e-learning
resources
Berlin 2001
Sunday 23.09.2001
Respiratory structure and function in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Are bronchodilator drugs really useful in COPD?
S. Valente, G. Iuliano, G. Pezzuto, D. Spina, G. Gualano, K. Geraneo, S. Cardo, M. De Rosa, F. Varone, G. Ciappi, G. M. Corbo (Rome, Italy)
Source:
Annual Congress 2001 - Respiratory structure and function in COPD
Session:
Respiratory structure and function in COPD
Session type:
Thematic Poster Session
Number:
674
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Valente, G. Iuliano, G. Pezzuto, D. Spina, G. Gualano, K. Geraneo, S. Cardo, M. De Rosa, F. Varone, G. Ciappi, G. M. Corbo (Rome, Italy). Are bronchodilator drugs really useful in COPD?. Eur Respir J 2001; 16: Suppl. 31, 674
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
The role of bronchodilator treatment in the prevention of exacerbations of COPD
Source: Eur Respir J 2012; 40: 1545-1554
Year: 2012
Bronchodilator treatment for asthma and COPD
Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Year: 2010
Is there a problem with inhaled corticosteroid use in COPD?
Source: Virtual Congress 2020 – Airway diseases
Year: 2020
What to use INSTEAD of inhaled corticosteroids in COPD?
Source: Eur Respir J 2014; 44: 1391-1393
Year: 2014
How the bronchodilatator in COPD patients works
Source: Eur Respir J 2004; 24: Suppl. 48, 288s
Year: 2004
Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Long-acting bronchodilators in COPD: where are we now and where are we going?
Source: Breathe 2014; 10:110-120
Year: 2014
Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015
Assessing bronchodilator response in patients with asthma and COPD using 19F-MRI
Source: Virtual Congress 2020 – New imaging techniques applied to old problems
Year: 2020
Bronchodilator therapies for severe asthma
Source: Eur Respir Mon 2011; 51: 253-267
Year: 2011
Magnetocardiographic assessment of therapeutic efficacy of β2–agonists and corticosteroids in patients with COPD and bronchial asthma
Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma
Year: 2008
Suppression of
F
ENO
with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice?
Source: ERJ Open Res, 5 (4) 00123-2019; 10.1183/23120541.00123-2019
Year: 2019
Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005
Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD
Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation
Year: 2015
Comparison of protective effect of bronchodilators in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD
Source: International Congress 2014 – Markers
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept